Melatonin potentiates the antitumor effect of curcumin by inhibiting IKKβ/NF-κB/COX-2 signaling pathway

SANDEEP SHRESTHA1*, JIABIN ZHU1*, QI WANG2, XIAOHUI DU3, FEN LIU2, JIANING JIANG2, JING SONG2, JINSHAN XING4, DONGDONG SUN5, QINGJUAN HOU5, YULIN PENG5, JUN ZHAO6, XIUZHEN SUN7 and XISHUANG SONG1

1Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 16011; 2Department of Respiratory Medicine, 3Scientific Research Center, 4Department of Neurosurgery, Affiliated Second Hospital of Dalian Medical University, Dalian, Liaoning 116023; 5College of Pharmacy, Dalian Medical University, Dalian, Liaoning 116044; 6Department of Neurosurgery, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011; 7Department of Otorhinolaryngology, Affiliated Second Hospital of Dalian Medical University, Dalian, Liaoning 116023, P.R. China

Received May 26, 2017; Accepted August 8, 2017
DOI: 10.3892/ijo.2017.4097

Abstract. Curcumin, a natural polyphenolic compound, has commonly been used as a food additive or in many traditional medicine remedies for over 2,000 years in many Asian countries. Melatonin is a hormone secreted from pineal glands of mammals and possesses diverse physiological functions. Both curcumin and melatonin have the effective potential to inhibit proliferation of various types of cancers, but there is no report on their combination for bladder cancer treatment, and the underlying mechanism remains poorly understood. In the present study, we investigated whether the combination of curcumin and melatonin leads to an enhanced inhibition of cell proliferation in bladder cancer cells. Our results showed that the combinational treatment enhanced the repression of nuclear translocation of NF-κB and their binding on COX-2 promoter via inhibiting IKKβ activity, resulting in inhibition of COX-2 expression. In addition, combined treatment with curcumin and melatonin induced cell apoptosis in bladder cancer through enhancing the release of cytochrome c from the mitochondrial intermembrane space into the cytosol. These results, therefore, indicated that melatonin synergized the inhibitory effect of curcumin against the growth of bladder cancer by enhancing the anti-proliferation, anti-migration, and pro-apoptotic activities, and provide strong evidence that combined treatment with curcumin and melatonin might exhibit an effective therapeutic option in bladder cancer therapy.

Introduction

Bladder cancer is one of the most malignant types of cancer, which ranks ninth among the overall cancers worldwide with an estimated 430,000 new cases diagnosed per year and caused 165,000 deaths in 2012 (1). Although radical cystectomy is introduced as the standard treatment for bladder cancer with neoadjuvant chemotherapy (2), the 5-year survival rate is still very low in patients, who suffer from invasive and metastatic bladder cancer (3,4). Thus, it is urgent to find novel therapeutic strategies and more effective agents to prolong and improve patients' survival and life quality, with no damage on normal cells.

Curcumin is a natural polyphenolic compound isolated from the rhizome of Curcuma longa (turmeric) (5), and has commonly been used as a food additive or in many traditional medicine remedies for over 2,000 years in many Asian countries (6). Previous studies have demonstrated that curcumin possesses various physiological and pharmacological properties as shown by in vitro and in vivo studies, including anti-oxidant, anti-bacterial, anti-inflammatory, immunomodulatory, free radical scavenging and anti-diabetic activities (7-10). In particular, curcumin could potentially inhibit cell proliferation, induce cell apoptosis and cell cycle arrest and suppress angiogenesis in a huge amount of cancers through modulating all kinds of molecular targets and signaling pathways (11-15). Furthermore, curcumin has been shown to induce apoptosis and cell cycle arrest and proliferation inhibition in bladder cancer cells (16,17). Although curcumin presents itself as a pharmacologically safe and effective potential candidate for anticancer therapy, its effectiveness is not powerful enough.
due to its side effects in high doses and other properties, such as poor absorption, rapid metabolism, and rapid systemic elimination (18). Therefore, increasing attention should be paid on combinational treatment of curcumin with other anti-tumor agents, especially natural antitumor compound, and the detailed molecular mechanisms of such combination deserve better investigation.

Melatonin is a major secretory product of pineal gland in vertebrates (19,20), modulating circadian rhythms, sleep, mood, reproduction and other biological processes (21,22). In the last few decades, many studies in vitro and in vivo have illustrated that melatonin had various physiological and pharmacological activities including anti-proliferation, anti-angiogenesis, anti-inflammatory, suppressing tumor metastasis and inducing cell apoptosis activities (23-26), by affecting multiple signaling pathways, including NF-kB (27). Based on its multiple physiological actions and low side-effects, more attempts deserve to be made to develop melatonin as an alternative chemopreventive or chemotherapeutic agent partner to form a better and novel strategy for cancer treatment, moreover, reducing their side effects.

Many reports have demonstrated cyclooxygenase-2 (COX-2), involved in inflammatory progression, and that it is can be inducible in response to certain stimuli such as growth factors and cytokines, thus, is causally associated with progression of many human tumors (28-30). Previous studies have indicated that COX-2 protein is highly expressed in a broad range of human tumors, including bladder cancer (31,32), and has been associated with high tumor aggressiveness and poor prognosis of patients (33,34). COX-2 expression is strictly and transcriptionally regulated by the recruitment of transactivators such as nuclear factor κB (NF-κB) to the corresponding sites of its promoters (35,36). Therefore, inhibition of COX-2 expression might be an effective way to inhibit the development of human tumors. However, whether curcumin could downregulate COX-2 expression and whether curcumin and melatonin combination could enhance this inhibition to further suppress bladder cancer cell growth remains poorly understood.

In the present study, we hypothesized that melatonin might play a role in potentiating or enhancing curcumin’s antitumor effect in human bladder cancer cells. To test this hypothesis, we analyzed the effects of this combinational mode on cell proliferation, migration, and apoptosis in bladder cancer cells, and detected some key changes in proteins to uncover the underlying molecular mechanisms. Our study showed that melatonin could be used as a potential combinational agent to sensitize the antitumor effect of curcumin. Such sensitization was mediated through IKKβ/NF-κB/COX-2 signaling pathways, implying that this combinational treatment might become an effective alternative approach in bladder cancer therapy.

**Materials and methods**

*Chemicals and reagents.* Curcumin and melatonin were purchased from Sigma-Aldrich (St. Louis, MO, USA). All reagents were dissolved in dimethyl sulfoxide (DMSO) as the initial concentrate and diluted with medium before use, and the final concentration of DMSO was <0.1%. Control cultures received the carrier solvent (0.1% DMSO).

*Antibodies and other materials.* Antibodies specific to cleaved caspase-3, COX-2, p-IKKβ, IKKβ, p-IκBα, IκBα, p65, β-actin and all the secondary antibodies were purchased from Cell Signaling Technology (Cell Signaling Technology, Inc., USA). Antibodies specific to cytochrome c, and p50 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies specific to Bcl-2, BAX, and Lamin B1 were purchased from Proteintech Group (Proteintech, Inc., USA). Antibodies specific to MMP-2/9 and TIMP-2 were purchased from Abcam. RPMI-1640 media, fetal bovine serum (FBS), and trypsin were purchased from Gibco. All other chemicals were purchased from Sigma Chemical Co. (St. Louis, MO, USA) unless otherwise specified.

*Cell culture.* Human bladder cancer cell lines T24, UMUC3 and 5637 were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in RPMI-1640 media, supplemented with 10% fetal bovine serum (FBS), and grown at 37°C in a humidified atmosphere with 5% CO₂. The authenticity of all these cell lines was verified through the genomic short tandem repeat (STR) profile by Shanghai Zhong Qiao Xin Zhou Biotechnology Co., Ltd., and the cell lines have been confirmed to be free of mycoplasma by Mycoplasma Detection Kit-Quick Test (Biotool).

*Cell viability assay.* Cell viability was measured using MTT assay. Briefly, 6x10⁴ cells were counted and seeded into 96-well culture plates followed by adhesion overnight, and then treated with appropriate concentrations of curcumin alone with and without melatonin. The quintuplicate was set for each concentration group. Followed by incubation for 48 h, 10 µl of MTT (5 mg/ml) was added to each well. For 4-h incubation at 37°C, the medium containing MTT was replaced by 0.15 ml DMSO. The absorbance was measured at 490 nm by EnSpire® Multimode Plate Reader (Perkin-Elmer, USA). Each experiment was repeated at least three times.

*Colony formation assay.* Bladder cancer cells were treated with curcumin or melatonin for 24 h, and then trypsinized into single cells and seeded into a 6-well plate at 1,500 cells/well. After being incubated at 37°C with 5% CO₂ for 10 days until colonies were large enough to be visualized, the cells were washed with PBS and fixed with the mixture (methanol: glacial acetic: ddH₂O =1:1:8) for 10 min, and stained with 0.1% crystal violet for 30 min.

*Wound healing assay.* Wound healing assay (scratch assay) was performed to detect cell migration. Briefly, UMUC3 and T24 cells were grown to full confluence in 6-well culture plates. After 6 h of serum starvation, the confluent cell monolayer was scraped with a sterile 100-µl pipette tip and treated with appropriate dose of curcumin or melatonin.

*Confocal immunofluorescence analysis.* For immunofluorescence analysis, T24 cells were seeded on coverslips, and treated with different concentrations of curcumin or melatonin for 48 h. After that, the cells were fixed with 4% paraformaldehyde at room temperature, and permeabilized with 0.2% Triton X-100, and then blocked in PBS containing 5% BSA. Subsequently, the cells were incubated with diluted
Reverse transcription-polymerase chain reaction (RT-PCR). Total RNA was extracted using TRizol reagent according to the kit protocol (Takara Bio, Dalian, China). cDNA was reverse-transcribed using the PrimeScript RT reagent kit (Takara Bio) according to the manufacturer's instructions. PCR analysis was performed on aliquots of the cDNA preparations to detect gene expression. Primer pairs were: COX-2, 5'-TCACAGGTCTTCAGCCGAGC-3' and 5'-TCGAGCTTCCATTGACCAG-3; β-actin, 5'-GCCACCCAGCACATGGA-3' and 5'-TGAAGGACTTGGTGGG-3'. Amplification products were analyzed on 1.5% agarose gel electrophoresis, stained with ethidium bromide, and photographed under ultraviolet light.

Flow cytometry analysis. To determine the distribution of the cells in the cell cycle and the proportion of apoptotic cells, flow cytometry analysis was performed using a flow cytometer (BD FACS Accuri C6; BD Biosciences, CA, USA). Briefly, the treated cells were collected and fixed with ice-cold 70% ethanol at 4°C for 4 h, and then stained with propidium iodide (PI) staining buffer (0.2% Triton X-100, 100 µg/ml DNase-free RNase A, and 50 µg/ml propidium iodide in PBS) in the dark for 30 min. For apoptosis examination, the treated cells were stained with Annexin V-FITC Apoptosis Detection kit in the dark at RT for 15 min. The cell cycle distribution and the fraction of apoptotic cells were determined using a FACs analysis system.

DNA ladder. T24 cells were cultured as described above using the different treatments. After the treatments, DNA was extracted and purified with an Apoptotic DNA Ladder kit (Beyotime, Shanghai, China) according to the manufacturer's instructions. An equal amount of purified apoptotic DNA was applied to electrophoresis on a 1.5% agarose gel, and the DNA bands were visualized by UV light and photographed.

Animal studies. Male nude mice (BALB/c nu/nu, 4 weeks old, 18-19 g) were purchased from SPF Laboratory Animal Center of Dalian Medical University (Dalian, China). Briefly, human T24 cells (5×10⁶ in 100 µl PBS) were injected subcutaneously near the axillary fossa of the nude mice. The tumor-bearing mice were randomly divided into four treatment groups with five mice in each group. Up to three weeks, when the tumor diameters reached 4×5 mm, group A was treated with propylene glycol; group B with 10 mg/kg melatonin; group C with 30 mg/kg curcumin; group D with 10 mg/kg melatonin and 30 mg/kg curcumin by intraperitoneal injection each day. Tumors were measured with a caliper every 2 days, and the tumor volume was calculated using the formula: V = 1/2 (width x length). Body weights were also recorded. After treatment for 11 days, all experimental mice were terminated with general anesthetic, ether and the total weight of the tumors in each mouse was measured.

To determine COX-2 expression, the tumor tissues were harvested and freshly fixed with 10% neutral formalin and desiccated and embedded in paraaffin. Sections (4 µm) were stained with hematoxylin and eosin, COX-2 antibody (1:150). The images were captured under a Leica DM 4000B fluorescence microscope equipped with a digital camera.

All the animals were given free access to sterilized food and water and were under habitation for 7 days before experiments. All procedures were in accordance with the recommendations established by Animal Care and Ethics Committee of Dalian Medical University as well as the guidelines by the US National Institutes of Health Guide for the Care and Use of Laboratory Animals. The protocol was approved by the Animal Care and Ethics Committee of Dalian Medical University.

Statistical analysis. The data are presented as the mean ± SD for at least three independent experiments. Statistical analysis was performed with SPSS 17.0 software. One-way analysis of variance (ANOVA) or Student's t-tests was used to evaluate the statistical significance between controls with treated groups. Results were considered statistically significant at the level of P<0.05.

Results

Melatonin and curcumin combination enhances the inhibition of cell proliferation. To determine whether melatonin could potentiate the inhibition of curcumin on bladder cancer cell proliferation, we first quantitatively analyzed the effect of melatonin or curcumin alone or their combination on cell proliferation and cell morphological change in human bladder cancer T24, UMUC3 and 5637 cells. As shown in Fig. 1A, treatment with melatonin or curcumin alone dose-dependently suppressed bladder cancer cell viability from 0.25 to 2 mM or 5 to 25 µM. However, combined with melatonin (1.0 mM) it could significantly enhance curcumin-mediated inhibition on cell viability as compared with curcumin alone in T24, UMUC3 and 5637 cells. The IC₅₀ values of curcumin alone
Shrestha et al: Melatonin synergizes antitumor activity of curcumin

or their combination for cell proliferation inhibition in the three cell lines were next calculated. As shown in Fig. 1B, the combined treatment with melatonin (1.0 mM) resulted in a marked reduction of the IC50 values when compared to the cells treated with curcumin alone. The T24 cells were more sensitive to combinational treatment than the other two cells (Fig. 1B).

Next, we detected the changes in cell morphology and spreading of T24 and UMUC3 cells with the combined treatment of melatonin and curcumin. As shown in Fig. 1C, the combined treatment exhibited highly reduced cell-to-cell contact and had lower spreading with fewer filopodia as compared with treatment with curcumin or melatonin alone. These results demonstrate that combination with melatonin enhanced the antitumor activity of curcumin in bladder cancer.

Melatonin and curcumin combination enhanced colony formation inhibition and cell cycle arrest. We next investigated the effect of curcumin in combination with melatonin on colony formation in bladder cancer cells by clonogenic cell survival assay. As shown in Fig. 2A, combinational treatment with melatonin and curcumin also significantly potentiated the inhibition of colony formation when compared with the single agent treatments in both T24 and UMUC3 cell lines. We next evaluated the degree of melatonin or curcumin alone or their combination on cell cycle arrest. As shown in Fig. 2B, treatment with curcumin alone induced cell cycle arrest at G2/M phase, whereas the combined treatment with melatonin exhibited a high percentage of G2/M phase.

Furthermore, to ascertain detailed mechanisms, the expression of key proteins involved in cell cycle (CDK1, cyclin A2, cyclin B1 and cyclin D1) were evaluated by western blotting in T24 cells at 48 h after treatment. We found that co-treatment with melatonin (1 mM) and curcumin (10 µM) resulted in dramatic reduction of the CDK1, cyclin A, cyclin B and cyclin D1 proteins (Fig. 2C). These data provide evidence that melatonin could sensitize curcumin-mediated cell proliferation inhibition, at least in part, by inducing cell cycle arrest at G2/M phase.

Melatonin and curcumin combination enhances the inhibition of cell migration and invasion. Wound healing assays and Transwell assays were employed to detect the combinational

---

Figure 1. Effect of melatonin and curcumin combination on cell proliferation and cell morphology changes in bladder cancer cells. (A) Human T24, UMUC3 and 5637 cells were treated with melatonin or curcumin alone or their combination at the indicated doses. At 48 h after treatment, the cell viability was determined by an MTT assay. The cells treated with vehicle control DMSO were used as the referent group with cell viability set at 100%. (B) The IC50 values of curcumin for cell viability inhibition in cells treated with or without melatonin (Mel) were determined. (C) The changes in cell morphology and spreading of T24 and UMUC3 cells treated with curcumin (10 µM) or melatonin (Mel) (1 mM) or their combination for 48 h were observed, and the cells were photographed using a microscope fitted with digital camera. Data are represented as the mean ± SD of three independent experiments. The level of significance is indicated by *P<0.05, **P<0.01.
effect of curcumin with melatonin on cell migration and invasion in human bladder cancer cells. Treatment with curcumin or melatonin (1 mM) alone suppressed cell migration and invasion; however, the combined treatment significantly enhanced this inhibition (Fig. 3A and C). Quantitative analysis for cell migration and invasion were calculated (Fig. 3B and D). Further, to ascertain detailed underlying mechanisms the combina-
tional mode on cell migration and invasion, the key protein
markers including matrix metalloproteinases (MMP-2/9) and
TIMP-2 were evaluated (Fig. 3E). These results confirmed that
melatonin enhanced the curcumin-mediated inhibitions of cell
migration and invasion in bladder cancer cells.

Melatonin and curcumin combination promotes cell apop-
tosis induction. We next determined whether the synergistic
inhibition of cell proliferation induced by curcumin and mel-
tonin combination is associated with the enhanced activation
of the apoptotic pathway in bladder cancer cells. As shown
in Fig. 4A, treatment with curcumin (10 µM) and melatonin
(1 mM) alone for 48 h induced 33.8 and 29.4% of the cells
to become apoptotic in T24 cells, respectively. Ho
ewever, the combination markedly enhanced cell apoptosis, resulting in
45.7% apoptotic cells (Fig. 4A). The apoptosis levels from
DNA ladder results were consistent with those from flow
cytometry analysis (Fig. 4C). We also detected the levels
of apoptosis-relative proteins (cleaved caspase-3, BAX and Bcl-2)
in 48 h-treated cells by western blotting. As shown in Fig. 4C,
the co-treatment with melatonin (1 mM) and curcumin
(10 µM) resulted in an increased level of the protein, the
cleaved caspase-3 and the ratio of Bax/Bcl-2.

Moreover, studies have shown that the release of cyto-
chrome c (cyt c) from mitochondria into cytosol could
induce apoptosis. We next performed immunofluorescence
imaging (IFI) analysis to confirm the co-localization of cyt c
and mitochondria to determine whether melatonin could
sensitize curcumin-mediated cyt c release. The results showed
that treatment with curcumin alone could effectively induce the release of cyt c from the intermitochondrial space into the cytosol in T24 cells, whereas co-treatment with melatonin greatly triggered the release of cyt c (Fig. 4D). Moreover, the protein level of cyt c was also detected in cytoplasm, where the mitochondrial fraction was isolated (Fig. 4E). These results indicate melatonin and curcumin combination promoted cell apoptosis induction by triggering cyt c release facilitating the caspase activation in the cytosol.

**Melatonin and curcumin combination enhances COX-2 signaling inhibition.** High expression of COX-2 is associated with cell proliferation, migration and invasion in cancer cells (31,32,37,38). We next evaluated the activities of crucumin and melatonin combination on COX-2 expression in bladder cancer cells at protein and mRNA levels by western blotting and RT-PCR. As shown in Fig. 5A and B, treatment with curcumin alone at the dose of 5 or 10 µM slightly inhibited COX-2 protein expression, while the combinational treatment with melatonin (1.0 mM) significantly decreased the expression of COX-2 in T24, UMUC3 and 5637 cells. Next, we pretreated T24 cells with a COX-2-selective inhibitor CB (50 µM) for 8 h, and followed with curcumin (10 µM) and melatonin (1.0 mM) co-treatment. After continuous incubation of 48 h, the cell viability was analyzed by MTT assay. As shown in Fig. 5C, treatment with CB or curcumin and melatonin alone significantly inhibited cell proliferation compared with control group, whereas CB pretreatment followed by curcumin and melatonin co-treatment did not significantly alter cell viability inhibition compared with treatment alone.
Furthermore, T24 cells were also incubated with melatonin (1.0 mM) and curcumin (10 µM) co-treatment after COX-2 inducer PMA (phorbol 12-myristate 13-acetate) pretreatment for 8 h, then cell mortality was evaluated. Our results showed that inducing exogenous COX-2 overexpression by PMA could restore the cell viability of melatonin and curcumin co-treatment (Fig. 5d). The above results implied that the enhanced proliferation inhibition of this combined mode might partially be mediated through suppressing COX-2 signaling.

Melatonin and curcumin combination enhanced the inhibition of NF-κB translocation and binding to COX-2 promoter. The above-mentioned results showed melatonin synergized the effect of curcumin to inhibit COX-2 expression, however COX-2 expression was regulated by several transcription factors and transcriptional coactivator on its promoter region, such as NF-κB (39). Then we carried out streptavidin-agarose pulldown assay to evaluate the enhancement of curcumin and melatonin co-treatment on NF-κB binding activities to COX-2 promoter by a DNA probe, which is a 478-bp biotin-labeled double-stranded oligonucleotide probe corresponding to the 5’-flanking sequence of the COX-2 gene from -30 to -508 (40). The results showed that combinational treatment with melatonin significantly suppressed NF-κB p65/p50 binding to COX-2 promoter DNA probe (Fig. 6A) as compared with curcumin treatment alone. We also detected the protein levels of NF-κB p50/p65 subunits in whole-cell lysates and nuclear lysates. As shown in Fig. 6B, p65/p50 protein levels in nuclear lysates decreased significantly in combinational treatment cells than in those treated with melatonin and curcumin alone, and different treatment has no obvious effects on the protein expression (Fig. 6C). To exclude the possibility of contamination
between cytoplasmic and nuclear fractions, we also checked the expression of β-actin in the nuclear fraction. No obvious contamination was found (Fig. 6C). From these results, we hypothesized that the combinational treatment markedly enhanced the inhibition of the translocation of NF-κB p65/p50 dimer proteins from cell cytoplasm to nucleus. To verify this hypothesis, immunofluorescence assays were carried out. As expected, treatment with curcumin alone suppressed NF-κB p65 translocation from cell cytoplasm to nucleus, while the co-treatment enhanced the suppression (Fig. 6D).

Previous studies have shown that only activated NF-κB p50/p65 dimers were able to translocate to the nucleus that then promoted gene transcription (41). Furthermore, NF-κB activation depends on IkB kinase (IKK) complex which is a major upstream kinase of IkBα in canonical NF-κB signaling pathway. Next, we investigated whether the combinational treatment exerted inhibition on IKK activity with an aim to explore the potential molecular mechanisms. As shown in Fig. 6E, combinational treatment with melatonin significantly decreased the protein levels of p-IκBα and p-IKKβ when compared to treatment with curcumin alone, while had little influence on overall IkBα and IKKβ expression. Moreover, we also detected the inhibition of curcumin and melatonin on IKKβ kinase activity in vitro using a cell IKKβ kinase activity spectrophotometry quantitative detection kit. As shown in Fig. 6F, the IKKβ kinase activity inhibition was similar to the above results. All of these results supported that melatonin and curcumin combination potentiated the suppression of NF-κB/COX-2 signaling through inhibition of IKKβ kinase activity.

Melatonin and curcumin combination inhibits tumor xenografts growth in nude mouse model. Based on the above results, we further investigated the potential of melatonin and curcumin co-treatment for tumor growth inhibition in a human bladder cancer xenograft mouse model. As shown in Fig. 7, both the tumor volume (Fig. 7A and C) and tumor weight (Fig. 7B) were inhibited by melatonin or curcumin alone. however, co-treatment with melatonin and curcumin together dramatically enhanced the growth inhibition of xenografts as compared with treatment with curcumin alone. In addition, the combined treatment did not affect significantly the body weight of the mice (Fig. 7D), and no other signs of acute or delayed toxicity were observed in the mice during treatment.
In addition, HE staining also showed that the tumor cells in PBS-treated control mice were of irregular shape, and had abundant cytoplasm and large and deformed nuclei (Fig. 7E). However, in the tumor cells co-treated with melatonin and curcumin group, the nuclei were smaller and more regular in shape than those in curcumin-treated group alone (Fig. 7E). Moreover, immunohistochemical staining was also performed to examine COX-2 expression in vivo. As shown in Fig. 7F, COX-2 expression was markedly suppressed by the combined treatment with melatonin and curcumin as compared with the control group. From the above results, it was confirmed that melatonin could synergize the effect of curcumin to suppress the growth of xenografted T24 cells by downregulating the expression of COX-2.

**Discussion**

Curcumin, as a therapeutic or preventive agent, is involved in a variety of antitumor cellular processes, especially used for human cancers treatment (16,17,42,43). A recent phase I clinical trial showed that curcumin could produce significant biological improvements and clinical response in patients when combining with other standard chemotherapy, such as docetaxel (44). Melatonin is also known to have antitumor properties in various types of cancer with low toxicity. However, curcumin or melatonin alone is not powerful enough to damage cancer, and adjunct therapy might be meaningful way to improve their efficacy in cancer therapy. In this study, we investigated the response of human bladder cancer cells...
ShRESTHA et al: MELATONIN SYNERGIZES ANTITUMOR ACTIVITY OF CURCUMIN

1258

to the combined treatment of melatonin and curcumin. Our results illustrated that melatonin could enhance curcumin mediated antitumor activity through triggering cytochrome c/caspase-dependent-apoptotic pathway, and inhibiting NF-κB/COX-2 signaling pathway via suppressing IKKβ activity. Here, to best of our knowledge, this is the first report that melatonin synergized the antitumor effect of curcumin in human bladder cancer cells and to demonstrate the underlying mechanisms of action.

COX-2 signaling is implicated in regulating physiological responses in many kinds of cancer cells. It is well-known that activation of nuclear factor-κB (NF-κB) p65/p50 contributes to COX-2 overexpression through binding to sites of its promoter (45,46). Our study demonstrated that the increased COX-2 expression inhibition by curcumin and melatonin co-treatment was very possibly mediated by repressing NF-κB dimer translocation from cytosol to nucleus and further resulting in COX-2 promoter binding inhibition, thereby abrogating COX-2 transcriptional activation in bladder cancer cells.

In canonical NF-κB signaling, IκB kinase (IKK) complex is required for its activation, which could rapidly lead to the inducible phosphorylation and degradation of IκB proteins. This complex is composed of two catalytic subunits (IKKα and IKKβ) and one regulatory subunit [IKKγ/NEMO (NF-κB essential modulator)] (47). However, IKKβ kinase plays key roles for phosphorylation of IκB proteins. Phosphorylated IκB proteins subsequently undergo proteasome-mediated degradation, thereby liberating free NF-κB p65/p50 dimers to translocate to the nucleus that can then modulate gene transcription (41). Therefore, it is essential to evaluate a therapy strategy selectively targeting IκKβ, and explore its underlying molecular mechanisms regulating NF-κB activation. The present study detected the enhanced inhibition of IκKβ activity after co-treatment with curcumin and melatonin in comparison with single agent treatment, suggesting that

Figure 7. Effect of melatonin and curcumin combination on tumor growth in a xenograft mouse model of human bladder cancer. An orthotopic mouse model of human T24 cells was used to evaluate the effect of melatonin and curcumin combination. The tumor images (A), tumor volume (B), tumor weight (C) and mouse body weights (D) were calculated. (E) H&E staining. (F) Immunohistochemical analysis of COX-2 protein expression in tumor samples. Neutral formalin-fixed tumor samples were prepared from animals and analyzed by immunohistochemical staining with rabbit anti-rabbit second antibody using the Vectastain Elite ABC kit, and examined under a microscope. Data were represented as the mean ± SD of three independent experiments. The level of significance is indicated by *P<0.05, **P<0.01.
inhibition of COX-2/NF-κB/IKKβ signaling at least partially contributed to melatonin enhanced curcumin mediated cell proliferation inhibition in bladder cancer cells.

The infiltrative growth is another major reason for tumor refractory tumor. Migration and invasion are two important prerequisites for infiltrative growth, and degradation of extracellular matrix is a key step. MMP-2 and MMP-9 as the prerequisites for infiltrative growth, and degradation of refractory tumor. Migration and invasion are two important greater than that expression but promoted TIMP-2 expression as compared to that the combined treatment significantly inhibited MMP-2/9 matrix of cells (48). Our results in this study demonstrated that the combined treatment significantly inhibited MMP-2/9 expression but promoted TIMP-2 expression as compared to the treatment with curcumin or melatonin alone, implying that enhancement of cell proliferation inhibition induced by curcumin and melatonin combination is associated with increased inhibition of cell migration and invasion in bladder cancer cells.

In our study, considering that T24 cells overexpress COX-2, and have a higher ability to form xenografts in nude mice and are more sensitive to combinational treatment than the other two cells (Fig. 1B), we performed in vitro experiments in T24 cells to study the molecular mechanism. However, from the nude mouse study, we found that the folds of increasing sensitivity on tumor growth inhibition in vivo study were not greater than that in vitro study by the two chemicals. It is probably because there are other factors in vivo that could affect the combined effects of the chemicals, such as metabolism by liver or excretion by kidney.

In conclusion, the present study demonstrated that melatonin synergized the ability of curcumin to inhibit bladder cancer growth, both in vitro and in vivo. Furthermore, we identified the underlying mechanisms, that is, the combinational treatment of curcumin and melatonin on bladder cancer cells is achieved through simultaneously targeting cyto c/caspase and IKKβ/NF-κB/COX-2 signaling. These findings provide new insights into the molecular mechanisms of the combinational treatment with curcumin and melatonin on bladder cancer cell growth inhibition and provide strong evidence that combined treatment with curcumin and melatonin might exhibit an effective therapeutic option in bladder cancer therapy.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (grant nos. 81271603 and 11472074).

References

1. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A and Bray F: Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 71: 96-108, 2017.
2. Wijtes JA: Bladder cancer in 2015: Improving indication, technique and outcome of radical cystectomy. Nat Rev Urol 13: 74-76, 2016.
3. Bellmunt J and Guix M: New agents for bladder cancer. Ann Oncol 21 (Suppl 7): vi56-vi58, 2010.
4. Anghel RM, Gales LN and Trifanescu OG: Outcome of uriniferous bladder cancer after combinational therapies. J Med Life 9: 95-100, 2016.
5. Shishodia S, Chaturvedi MM and Aggarwal BB: Role of curcumin in cancer therapy. Curr Probl Cancer 31: 243-305, 2007.
6. Gupta SC, Kismali G and Aggarwal BB: Curcumin, a component of turmeric: From farm to pharmacy. Biofactors 39: 2-13, 2013.
7. Shehzad A and Lee YS: Curcumin: Multiple molecular targets mediate multiple pharmacological actions - A review. Drugs Future 35: 113-119, 2010.
8. Buehler V, Ferrari E, Laszardi S, Bellutti S, Pignedoli F and Imbriano C: Curcumin derivatives: Molecular basis of their anti-cancer activity. Biochem Pharmacol 78: 1305-1315, 2009.
9. Shehzad A, Wahid F and Lee YS: Curcumin in cancer chemoprevention: Molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343: 489-499, 2010.
10. Gupta SC, Patchva S, Koh W and Aggarwal BB: Discovery of curcumin, a component of golden spice, and its miraculous biological activities. Clin Exp Pharmacol Physiol 39: 283-299, 2012.
11. Chen J, He ZM, Wang FL, Zhang ZS, Liu XZ, Zhai DD and Chen WD: Curcumin and its promise as an anticancer drug: An analysis of its anticancer and antifungal effects in cancer and associated complications from invasive fungal infections. Eur J Pharmacol 772: 33-42, 2016.
12. Kasi PD, Tamilselvam R, Skalicka-Wozniak K, Nabavi SF, Daglia M, Bishayee A, Pazoiki-Toroudi H and Nabavi SM: Molecular targets of curcumin for cancer therapy: An updated review. Tumour Biol 37: 13017-13028, 2016.
13. Rahman AH, Al Zohairy MA, Aly SM and Khan MA: Curcumin: A potential candidate in prevention of cancer via modulation of molecular pathways. Biomed Res Int 2014: 761608, 2014.
14. Li Y and Zhang T: Targeting cancer stem cells by curcumin and melatonin synergized the ability of curcumin to inhibit bladder cancer growth, both in vitro and in vivo. Curr Probl Cancer 31: 243-305, 2007.
15. Tuorkey MJ: Curcumin a potent cancer preventive agent: Mechanisms of cancer cell killing. Interv Med Appl Sci 6: 139-146, 2014.
16. Kang M, Ho JN, Kook HR, Lee S, Oh JJ, Hong SK, Lee SE and Byun SS: Thera curcumin® efficiently inhibits the growth of human prostate and bladder cancer cells via induction of apoptotic cell death and cell cycle arrest. Oncol Rep 35: 1463-1472, 2016.
17. Liu HS, Ke CS, Cheng HC, Huang CY and Su CL: Curcumin-induced mitotic spindle defect and cell cycle arrest in human bladder cancer cells occurs partly through inhibition of aurora A. Mol Pharmacol 80: 638-646, 2011.
18. Anand P, Kunnumakkara AB, Newman RA and Aggarwal BB: Bioavailability of curcumin: Problems and promises. Mol Pharm 4: 807-818, 2007.
19. McIsaac WM, Farrell G, Taborsky RG and Taylor AN: Indole compounds: Isolation from pineal tissue. Science 148: 102-103, 1965.
20. Packer L, Case JD and Takahashi Y: Isolation of melatonin and 5-methoxyindole-3-acetic acid from bovine pineal glands. J Biol Chem 235: 1992-1997, 1960.
21. Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS and Slominski AT: Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol Cell Endocrinol 351: 152-166, 2012.
22. Singh M and Jadhav HR: Melatonin: Functions and ligands. Drug Discov Today 19: 1410-1418, 2014.
23. Rondonelli M, Faliva MA, Penna S and Antoniello N: Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: Review and remarks. Aging Clin Exp Res 25: 499-510, 2013.
24. García JJ, López-Pingarrón L, Almeida-Souza P, Tres A, Escudero P, García-Gil FA, Tan DX, Reiter RJ, Ramírez JM and Bernal-Pérez M: Protective effects of melatonin in reducing oxidative stress and in preserving the fluidity of biological membranes: A review. J Pineal Res 56: 225-237, 2014.
25. Xin Z, Jiang S, Jiang P, Yan X, Fan C, Di S, Wu G, Yang Y, Reiter RJ and Ji G: Melatonin as a treatment for gastrointestinal cancer: A review. J Pineal Res 58: 375-387, 2015.
26. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, Brimer M, Hauch A, Lundberg PW, Summers W, Yuan L, et al: Melatonin: An inhibitor of breast cancer. Endocr Relat Cancer 22: R183-R204, 2015.
27. Ordoñez R, Carbajal-Pescador S, Prieto-Dominguez N, García-Palomona, Gonzalez-Gallego J and Mauriz JL: Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J Pineal Res 56: 20-30, 2014.
28. Marks F, Müller-Decker K and Försterberger G: A causal relationship between unscheduled eicosanoid signaling and tumor development: Cancer chemoprevention by inhibitors of arachidonic acid metabolism. Toxicology 153: 11-26, 2000.
29. Federico A, Morgillo F, Tuccillo C, Ciardiello F and Loguercio C: Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121: 2381-2386, 2007.

30. Nakanishi M and Rosenberg DW: Roles of cPLA2alpha and arachidonic acid in cancer. Biochim Biophys Acta 1761: 1335-1343, 2006.

31. Wan GX, Chen P, Yu XJ, Di QS, Yu YD, Lei JH, Tai YY and Cao FJ: Cyclooxygenase-2 polymorphisms and bladder cancer risk: A meta-analysis based on case-control studies. Int J Clin Exp Med 8: 3933-3945, 2015.

32. Matsuo T, Miyata Y, Mitsunari K, Yasuda T, Ohba K and Sakai H: Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: Correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2. Oncol Lett 13: 275-280, 2017.

33. Festa-Vasconcellos JS, Piranda DN, Amaral LM, Indio-do-Brasil V, Kofman S and Vianna-Jorge R: Polymorphisms in cycloxygenase-2 gene and breast cancer prognosis: Association between PTGS2 haplotypes and histopathological features. Breast Cancer Res Treat 132: 251-258, 2012.

34. Chen G, Li X, Yang J, Li J, Wang X, He J and Huang Z: Prognostic significance of cyclooxygenase-2 expression in patients with hepatocellular carcinoma: A meta-analysis. Arch Med Sci 12: 1110-1117, 2016.

35. Park E-J, Cheenpracha S, Chang LC, Kondratyuk TP and Pezzuto JM: Inhibition of lipopolysaccharide-induced cyclooxygenase-2 and inducible nitric oxide synthase expression by 4-[(2'-O-acetyl-α-L-rhamnosyloxy)benzyl]isothiocyanate from Moringa oleifera. Nutr Cancer 63: 971-982, 2011.

36. Asting AG, Caren H, Andersson M, Lomroth C, Lagerstedt K and Lundholm K: COX-2 gene expression in colon cancer tissue related to regulating factors and promoter methylation status. BMC Cancer 11: 238, 2011.

37. Jiang J and Dingledine R: Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation. J Pharmacol Exp Ther 344: 360-367, 2013.

38. Jiang J and Dingledine R: Prostaglandin receptor EP2 in the crosshairs of anti-inflammation, anti-cancer, and neuroprotection. Trends Pharmacol Sci 34: 413-423, 2013.

39. Zhang C, Su Z-Y, Wang L, Shen L, Yang Y, Guo Y, Pung D, Bountra C and Kong AN: Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1. Biochem Pharmacol 117: 35-45, 2016.

40. Yu ZL, Guo W, Ma XC, Zhang B, Dong P, Huang L, Wang X, Wang C, Hsu X, Yu W, et al: Gamabufotalin, a bufadienolide from toad venom, suppresses COX-2 expression through targeting IKK/NF-κB signaling pathway in lung cancer cells. Mol Cancer 13: 203, 2014.

41. Karin M and Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663, 2000.

42. Bimonte S, Barbieri A, Leonigto M, Piccirillo M, Giudice A, Piveniello C, de Angelis C, Granata V, Palma R and Izzo F: Curcumin anticancer studies in pancreatic cancer. Nutrients 8: 8, 2016.

43. Charpentier MS, Whipple RA, Vitolo MI, Boggs AE, Slovic J, Thompson KN, Bhandary L and Martin SS: Curcumin targets breast cancer stem-like cells with microtentacles that persist in mammospheres and promote reattachment. Cancer Res 74: 1250-1260, 2014.

44. Bayet-Robert M, Kwiatkowski F, Leheurteur M, Gachon F, Planchat E, Abrial C, Mouret-Reynier MA, Durando X, Barthomeuf C and Chollet P: Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer Biol Ther 9: 8-14, 2010.

45. Garcia-Rivera D, Delgado R, Bougarne N, Haegeman G and Bergho WV: Gallic acid indanone and mangiferin xanthone are strong determinants of immunosuppressive anti-tumour effects of Mangifera indica L. bark in MDA-MB231 breast cancer cells. Cancer Lett 305: 21-31, 2011.

46. Kim H-N, Kim D-H, Kim E-H, Lee MH, Kundu JK, Na HK, Cha YN and Surh YJ: Sulforaphane inhibits phorbol ester-stimulated IKK-NF-κB signaling and COX-2 expression in human mammary epithelial cells by targeting NF-κB activating kinase and ERK. Cancer Lett 351: 41-49, 2014.

47. Xia Y, Shen S and Verma IM: NF-κB, an active player in human cancers. Cancer Immunol Res 2: 823-830, 2014.

48. Pittayapruek P, Meephansan J, Prapapan O, Komine M and Ohtsuki M: Role of matrix metalloproteinases in photaging and photocarcinogenesis. Int J Mol Sci 17: 868, 2016.